Ovarian Cancer Trial, Recruiting (NCT05574673)

Ovarian Cancer Trial, Recruiting NCT05574673 Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit Condition: Ovarian Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05574673 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ovarian Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been recently diagnosed with epithelial ovarian cancer (a specific type of ovarian cancer) that has been confirmed by a tissue test (biopsy)
If your cancer is at an early stage (Stage I or II), you have a known change (mutation) in the BRCA1 or BRCA2 gene, either inherited or found in the tumor itself
If your cancer is at a later stage (Stage III or IV), you may have any type of epithelial ovarian cancer
You are a woman aged 18 or older at the time of your diagnosis
Your doctors are planning to treat you with a platinum-based chemotherapy
You are able to understand and sign a consent form agreeing to take part in the study
You are willing to provide a stored tissue sample from your tumor

Who may not be able to join:

Your ovarian cancer is not of the epithelial type, is classified as a "borderline tumor," or is of a type called mucinous
Your cancer is at an early stage (Stage I or II) and you do not have a BRCA1 or BRCA2 gene mutation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mansoor R Mirza, MD, NSGO-CTU

Phone: 004535453311

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05574673

Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Phase: Not Applicable

Status: Recruiting

Condition: Ovarian Cancer

Trial contact: 004535453311

More information: https://clinicaltrials.gov/study/NCT05574673

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been recently diagnosed with epithelial ovarian cancer (a specific type of ovarian cancer) that has been confirmed by a tissue test (biopsy)
If your cancer is at an early stage (Stage I or II), you have a known change (mutation) in the BRCA1 or BRCA2 gene, either inherited or found in the tumor itself
If your cancer is at a later stage (Stage III or IV), you may have any type of epithelial ovarian cancer
You are a woman aged 18 or older at the time of your diagnosis
Your doctors are planning to treat you with a platinum-based chemotherapy
You are able to understand and sign a consent form agreeing to take part in the study
You are willing to provide a stored tissue sample from your tumor

Who may not be able to join:

Your ovarian cancer is not of the epithelial type, is classified as a "borderline tumor," or is of a type called mucinous
Your cancer is at an early stage (Stage I or II) and you do not have a BRCA1 or BRCA2 gene mutation

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Registry

ClinicalTrials.gov

Start date

1 December 2022

Est. completion

1 May 2028

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Endpoint OP1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov